Skip to main content
Hit enter to search or ESC to close
Close Search
Hepion PharmaceuticalsHepion Pharmaceuticals
Menu
  • About
    • Leadership
    • Board of Directors
  • Portfolio
    • Hepatocellular Carcinoma
    • Gravitas Life Sciences
  • Newsroom
  • Investors
    • Investor Overview
    • Press Releases
    • Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact
    Hepion Pharmaceuticals

    Newsroom

    • Press Releases
    • Media Contact
    • News Alerts

    Recent Press Releases

    Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication
    October 19, 2026
    Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
    October 14, 2026
    View All Press Releases

    Hepion Pharmaceuticals, Inc.,
    22 West Street
    Suite 1B
    Red Bank, NJ 07701
    OTCQB: HEPA

    908-450-6581
    info@hepionpharma.com

    Subscribe to Receive News Alerts

    About
    Newsroom
    Investors
    Contact
    Subscribe for Updates

    © 2026 Hepion Pharmaceuticals | Disclaimer & Terms of Use

    Close Menu
    • About
      • Leadership
      • Board of Directors
    • Portfolio
      • Hepatocellular Carcinoma
      • Gravitas Life Sciences
    • Newsroom
    • Investors
      • Investor Overview
      • Press Releases
      • Presentations
      • Stock Information
      • SEC Filings
      • Corporate Governance
    • Contact